Addex Pharmaceuticals S.A. (ADXN) Addex Increases Issued Share Capital to...
Addex Increases Issued Share Capital to Create Treasury Shares Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 15, 2023 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex mGlu2PAM Demonstrates Potential in...
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder Data published in Neuropharmacology shows mGlu2 PAMs attenuate oxycodone use and potential as a novel treatment for opioid use disorder...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex GABAB Positive Allosteric Modulator...
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration Discovery collaboration on track to...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Therapeutics to Release Half-Year...
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023 Geneva, Switzerland, August 3, 2023 – (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Reports 2023 Half Year and Second...
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update ADX71149 Phase 2 epilepsy clinical study Cohort 2 continues recruiting following the Independent Interim...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex’s Dipraglurant Development in...
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex mGlu2 NAM Cognition Program Receives...
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant Addex led consortium wins Eurostars grant to deliver clinical candidates to treat mild neurocognitive disorders Ad Hoc Announcement Pursuant...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Announces Plan to Implement ADS Ratio...
Addex Announces Plan to Implement ADS Ratio Change Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 6, 2023 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Completes ADS Ratio Change
Addex Completes ADS Ratio Change Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 20, 2023 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Announces Participation in the...
Addex Announces Participation in the Bio-Europe 2023 Conference Geneva, Switzerland, November 2, 2023 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Regains Nasdaq Listing Compliance
Addex Regains Nasdaq Listing Compliance Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 8, 2023 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex ADX71149 Epilepsy Phase 2 Study...
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients Top line results expected in Q2 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 14, 2023 - (SIX...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Therapeutics to Release Third Quarter...
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023 Geneva, Switzerland, November 23, 2023 - (SIX and Nasdaq: ADXN), a clinical-stage...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Convenes Extraordinary General Meeting
Addex Convenes Extraordinary General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 28, 2023 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Reports Q3 2023 Financial Results and...
Addex Reports Q3 2023 Financial Results and Provides Corporate Update ADX71149 Phase 2 epilepsy clinical study completes recruitment of patients, with top line results expected in Q2 2024mGlu2 NAM...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Creates Treasury Shares
Addex Creates Treasury Shares Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 14, 2023 - (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Shareholders Approve All Resolutions...
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 20, 2023 - (SIX: ADXN and Nasdaq: ADXN), a...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex to Present at Biotech Showcase™ 2024
Addex to Present at Biotech Showcase™ 2024 CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - (SIX and Nasdaq: ADXN), a...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex to Present at the Swiss Equities...
Addex to Present at the Swiss Equities Baader Conference Geneva, Switzerland, January 9, 2024 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Enters into At-The-Market ADS...
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 31, 2024 – Addex Therapeutics (SIX:...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex to Present at the Bio-Europe Spring...
Addex to Present at the Bio-Europe Spring 2024 Conference Geneva, Switzerland, March 14, 2024 – (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex and Perceptive Launch Neurosterix...
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders Addex receives CHF5M and 20% share of Neurosterix...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Therapeutics to Release Full-Year...
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024 Geneva, Switzerland, April 11, 2024 – (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex Therapeutics Reports Full Year 2023...
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with...
View ArticleAddex Pharmaceuticals S.A. (ADXN) Addex to Present at the Swiss Biotech Day 2024
Addex to Present at the Swiss Biotech Day 2024 Geneva, Switzerland, April 19, 2024 - (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug...
View Article
